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A B S T R A C T
Background
Pneumocystis jiroveci pneumonia (PCP) remains themost common opportunistic infection in patients infected with the human immun-
odeficiency virus (HIV). Among patients with HIV infection and PCP the mortality rate is 10% to 20% during the initial infection and
this increases substantially with the need for mechanical ventilation. It has been suggested that corticosteroids adjunctive to standard
treatment for PCP could prevent the need for mechanical ventilation and decrease mortality in these patients.
Objectives
To assess the effects of adjunctive corticosteroids on overall mortality and the need for mechanical ventilation in HIV-infected patients
with PCP and substantial hypoxaemia (arterial oxygen partial pressure < 70 mmHg or alveolar-arterial gradient > 35 mmHg on room
air).
Search methods
For the original review we searchedThe Cochrane Library (2004, Issue 4), MEDLINE (January 1980 to December 2004) and EMBASE
(January 1985 to December 2004) without language restrictions. We further reviewed the reference lists from previously published
overviews, searched UptoDate version 2005 and Clinical Evidence Concise (Issue 12, 2004), contacted experts in the field and searched
the reference lists of identified publications for citations of additional relevant articles.
In this update of our review, we searched the above-mentioned databases in September 2010 and April 2014 for trials published since
our original review. We also searched for ongoing trials in ClinicalTrials.gov and the World Health Organization International Clinical
Trial Registry Platform (ICTRP). We searched for conference abstracts via AEGIS.
Selection criteria
Randomised controlled trials that compared corticosteroids to placebo or usual care in HIV-infected patients with PCP in addition
to baseline treatment with trimethoprim-sulfamethoxazole, pentamidine or dapsone-trimethoprim, and reported mortality data. We
excluded trials in patients with no or mild hypoxaemia (arterial oxygen partial pressure > 70 mmHg or an alveolar-arterial gradient <
35 mmHg on room air) and trials with a follow-up of less than 30 days.
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Data collection and analysis
Two teams of review authors independently evaluated the methodology and extracted data from each primary study. We pooled
treatment effects across studies and calculated a weighted average risk ratio of overall mortality in the treatment and control groups
using a random-effects model.
In this update of our review, we used the GRADE methodology to assess evidence quality.
Main results
Of 2029 screened records, we included seven studies in the review and six in the meta-analysis. Risk of bias varied: the randomisation
and allocation process was often not clearly described, five of seven studies were double-blind and there was almost no missing data.
The quality of the evidence for mortality was high. Risk ratios for overall mortality for adjunctive corticosteroids were 0.56 (95%
confidence interval (CI) 0.32 to 0.98) at one month and 0.59 (95% CI 0.41 to 0.85) at three to four months of follow-up. In adults,
to prevent one death, numbers needed to treat are nine patients in a setting without highly active antiretroviral therapy (HAART)
available, and 23 patients with HAART available. The three largest trials provided moderate quality data on the need for mechanical
ventilation, with a risk ratio of 0.38 (95% CI 0.20 to 0.73) in favour of adjunctive corticosteroids. One study was conducted in infants,
suggesting a risk ratio for death in hospital of 0.81 (95% CI 0.51 to 1.29; moderate quality evidence).
Authors’ conclusions
The number and size of trials investigating adjunctive corticosteroids for HIV-infected patients with PCP is small, but the evidence
from this review suggests a beneficial effect for adult patients with substantial hypoxaemia. There is insufficient evidence on the effect
of adjunctive corticosteroids on survival in infants.
P L A I N L A N G U A G E S U M M A R Y
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Pneumocystis jiroveci pneumonia (PCP), formerly called Pneumocystis carinii pneumonia, is the most common opportunistic infection
among patients infected with HIV. In 1990, based on evidence from five randomised controlled trials, an expert panel recommended
the use of corticosteroids for HIV-infected patients with PCP and substantial hypoxaemia (low levels of oxygen in the blood).
The objective of this systematic review was to assess the effects of adjunctive (additional) corticosteroids on mortality and the need for
mechanical ventilation in patients co-infected with HIV and PCP. We searched for eligible studies up to April 2014. We included seven
studies in this review and six in the meta-analysis (combining of study data).
The number and size of the trials investigating adjunctive corticosteroids for HIV-infected patients co-infected with PCP is small (the
six trials included in the meta-analysis comprised 242 individuals in the intervention groups and 247 individuals in the control groups;
the trial on infants comprised 47 individuals in the intervention group and 53 in the control group). Follow-up ranged from three to
14 months. The evidence from this review was of high quality for mortality and of moderate quality for need for mechanical ventilation
and suggests a beneficial effect for adult patients with substantial hypoxaemia. For infants (18 months or younger) with HIV and
suspected PCP there is insufficient evidence on whether the effect of adjunctive corticosteroids could improve survival (the confidence
interval for the estimate of effect is wide, includes both clinically relevant benefit and harm and is of moderate quality).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Adjunctive corticosteroids versus no such treatment for Pneumocystis jiroveci pneumonia in patients with HIV infection
Patient or population: patients with Pneumocystis jiroveci pneumonia and HIV infection
Settings: hospital
Intervention: adjunctive corticosteroids
Comparison: no adjunctive corticosteroids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Without adjunctive corti-
costeroids
With adjunctive corti-
costeroids
Death at 1 month
(adults)
Study population1 RR 0.56
(0.32 to 0.98)
489
(6 studies)
⊕⊕⊕⊕
high2,3,4
247 per 1000 138 per 1000
(79 to 242)
Low1
100 per 1000 56 per 1000
(32 to 98)
High1
250 per 1000 140 per 1000
(80 to 245)
Death at 3 to 4 months
(adults)
Study population1 RR 0.59
(0.41 to 0.85)
448
(5 studies)
⊕⊕⊕⊕
high2
258 per 1000 152 per 1000
(106 to 219)
Low13
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100 per 1000 59 per 1000
(41 to 85)
High1
250 per 1000 147 per 1000
(102 to 213)
Death in hospital; chil-
dren
472 per 1000 382 per 1000
(241 to 608)
RR 0.81
(0.51 to 1.29)
100
(1 study)
⊕⊕⊕©
moderate5
Need for mechanical
ventilation at 1 month
164 per 1000 62 per 1000
(33 to 120)
RR 0.38
(0.2 to 0.73)
388
(3 studies)
⊕⊕⊕©
moderate6
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1In Western countries where HAART is widely available the mortality rate is 10%; in developing countries where HAART is often not
available the mortality rate is 25%.
2Lack of blinding was judged as less relevant to the outcome of mortality.
3Inconsistency among trials could be explained by the difference in the initiation of corticosteroids - all trials report starting corticosteroids
within 3 days, but in Clement 1989 the majority of patients started corticosteroids after 2 days.
4The confidence interval of the summary estimate from all trials has an upper boundary close to 1 (no effect); however, if Clement 1989
(the trial introducing heterogeneity and initiating steroids later than other trials) is excluded in a sensitivity analysis, the upper boundary
of the summary estimate changes to 0.7, i.e. all plausible effects are clinically relevant.
5Quality of evidence downgraded from high to moderate as there was only a single trial with a wide confidence interval of treatment
effect including clinically relevant benefit and clinically relevant harm.
6Quality of evidence downgraded from high to moderate because lack of blinding could influence the decision of a caregiver to initiate
mechanical ventilation.
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B A C K G R O U N D
Description of the condition
With the introduction of highly active antiretroviral therapy
(HAART)more than twodecades ago, the incidence ofPneumocys-
tis jiroveci pneumonia (Stringer 2002) has decreased significantly
in the Western hemisphere. However, PCP (the acronym stands
for pneumocystis pneumonia) still remains one of the most com-
mon opportunistic infections in patients infected with the human
immunodeficiency virus (HIV) (Kaplan 2000). Among patients
with HIV infection and PCP the mortality rate is 10% to 20%
during the initial infection and this increases substantially with
the need for mechanical ventilation (Randall 2000).
Description of the intervention
Two to three days after starting anti-PCP therapy, the respiratory
situation of PCP patients often worsens because of increased in-
flammation in the lungs as a reaction to pneumocystis particles
from killed organisms. Corticosteroids given in conjunction with
anti-PCP therapy may help to better control the inflammatory
process. Therefore the corticosteroid treatment should be started
as early as possible but within 72 hours after starting the PCP-spe-
cific therapy. So far, there is no evidence about an optimal dose or
duration of adjunctive corticosteroids. The following 21-day oral
regimen with prednisone has been recommended: 40 mg orally
twice daily for days one to five, 40 mg once daily for days six to
10, and 20 mg once daily for days 11 to 21 (Benson 2004; EACS
2013). If parenteral administration is necessary, it is recommended
to use methylprednisolone at 75% of the respective prednisone
dose (CDC 2013). In childrenwith severe PCP, it is recommended
to start the corticosteroid treatment as early as possible but within
72 hours after diagnosis. The recommended dose of prednisone
for children is 1 mg/kg of body weight twice daily for days one to
five, 0.5 mg/kg once daily for days six to 10, and 0.5 mg/kg once
daily for days 11 to 21 (NIH 2013). The alternative regimen with
methylprednisolone (intravenous) is 1 mg/kg/dose every six hours
for days one to seven, 1 mg/kg/dose once daily for days eight to
nine, 0.5 mg/kg/dose twice daily for days 10 to 11, and 1 mg/kg/
dose once daily for days 12 to 16 (NIH 2013).
How the intervention might work
Within two to three days of the initiation of anti-PCP therapy,
the health status of patients often worsens. It is presumed that the
patient’s alveolar-arterial oxygen gradient and the inflammatory
processes in the lungs increase as organisms are killed (Sax 2012).
Adjunctive corticosteroids administered with initiation of anti-
PCP therapy may reduce the inflammatory process and prevent
this clinical worsening.
Why it is important to do this review
In 1990, an expert panel recommended the use of corticosteroids
for HIV-infected patients with PCP and substantial hypoxaemia
(initial arterial oxygen partial pressure of < 70 mmHg or alveolar-
arterial gradient > 35 mmHg on room air) based on the evidence
from five randomised controlled trials (Consensus 1990). The
studies used for the consensus statement still represent the basis for
the current guidelines for the treatment of adults (CDC 2013) and
children (NIH 2013). However, at the time of the first consensus
statement, one trial was not yet completed (Nielsen 1992), two
trials had been stopped prematurely (Gagnon 1990; Montaner
1990), and one trial was not published in full (Clement 1989).
In 1992, a systematic review qualitatively summarised the same
incomplete data (Sistek 1992).
O B J E C T I V E S
To assess the effects of adjunctive corticosteroids on overall mor-
tality and the need for mechanical ventilation in HIV-infected pa-
tients with PCP and substantial hypoxaemia (arterial oxygen par-
tial pressure < 70 mmHg or alveolar-arterial gradient > 35 mmHg
on room air).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered trials eligible for this review if they used random
allocation of participants into parallel groups and reported mor-
tality data. We excluded trials with a follow-up of less than 30
days.
Types of participants
All HIV-infected patients with moderate-severe PCP, defined as
PCP with substantial hypoxaemia. We excluded patients with no
or mild hypoxaemia (arterial oxygen partial pressure > 70 mmHg
or an alveolar-arterial gradient < 35 mmHg on room air).
Types of interventions
We included studies if they compared corticosteroids to placebo or
usual care in HIV-infected patients with PCP in addition to base-
line treatment with trimethoprim-sulfamethoxazole, pentamidine
or dapsone-trimethoprim.
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Types of outcome measures
The main outcome measure of interest was overall mortality at
one and three to four months of follow-up.
A secondary outcome measure was the need for mechanical ven-
tilation.
Search methods for identification of studies
Electronic searches
We searched The Cochrane Library (2004, Issue 4), MEDLINE
(January 1985 to December 2004) and EMBASE (January 1985
to December 2004) without language restrictions to identify
randomised controlled trials that compared adjunctive corticos-
teroids to control in HIV-infected patients with PCP. We used
the terms steroid*, corticosteroid*, glucocorticoid*, Pneumocys-
tis, PCP, *carinii and *jiroveci as text words and Glucocorti-
coids, Adrenal Cortex Hormones, Steroids, Pneumocystis Infec-
tions, Pneumocystis jiroveci and Pneumonia, Pneumocystis as Med-
ical Subject Headings. We restricted the search to articles indexed
as randomised controlled trials (publication type) or drug ther-
apy (subject heading) or those that included the words random*
or placebo in their titles or abstracts. In this review update, we
searched the above-mentioned databases in September 2010 and
April 2014 for trials published since our original review. A detailed
search strategy is presented in Appendix 1.
Searching other resources
We further reviewed the reference lists from previously published
overviews (Consensus 1990; Sistek 1992), searchedUptoDate ver-
sion 2005 and Clinical Evidence Concise (Issue 12, 2004), con-
tacted experts in the field and searched the reference lists of iden-
tified publications for citations of additional relevant articles. In
this update of our review, we searched for ongoing trials in Clin-
icalTrials.gov and the World Health Organization International
Clinical Trial Registry Platform (ICTRP). We searched for con-
ference abstracts via AEGIS.
Data collection and analysis
Selection of studies
Two teams of investigators (MB/HCBandRB/HF) independently
assessed study eligibility and quality and resolved any disagreement
by consensus. We abstracted data from eligible trials in duplicate.
HR and MB assessed trials identified during the update in 2010;
HE and MB assessed potentially eligible trials identified in 2014.
Assessment of risk of bias in included studies
We assessed the risk of bias of the included trials with respect to
random sequence generation; concealment of treatment alloca-
tion; blinding of patients, caregivers or assessors of clinical out-
comes; completeness of follow-up; performance of a sample size
calculation; and whether the trial was stopped early for benefit
(Juni 1999; Montori 2005). HR and MB assessed trials identified
during the update in 2010; HE and MB assessed potentially eli-
gible trials identified in 2014.
Assessment of heterogeneity
We tested for heterogeneity with the Cochrane Q test and mea-
sured inconsistency of treatment effects across studies using the
I2 statistic (the percentage of total variance across studies that is
due to heterogeneity rather than chance) (Higgins 2002; Higgins
2003).
Assessment of reporting biases
We investigated the presence of publication bias by means of fun-
nel plots (Sterne 2001).
Data synthesis
Weperformed all analyses according to the intention-to-treat prin-
ciple, i.e. we analysed patients in the groups to which they were
randomised. In our main analysis we assumed that patients lost
to follow-up did not have an event. In a sensitivity analysis we
assumed that patients lost to follow-up experienced an event. We
pooled treatment effects across studies and calculated a weighted
average risk ratio of overall mortality in the treatment and control
groups using a random-effects model. We performed statistical
analyses using Review Manager 5.3 (RevMan 2014). We calcu-
lated numbers needed to treat to prevent one death bymultiplying
the mean relative risk reduction with an initial mean baseline risk
(Marx 2003).
Sensitivity analysis
We carried out sensitivity analyses to examine treatment effects
according to quality components of trials, whether the publication
was a peer-reviewed article or just in abstract form, and whether
trials were stopped early for benefit versus not.
’Summary of findings’ table
In this update of our review, we used the GRADE methodology
to assess the quality of the evidence (Guyatt 2008). We have pre-
sented the quality of the evidence for the following outcomes in a
’Summary of findings’ table:
1. death at one month (adults);
2. death at three to four months (adults);
3. death in hospital (children).
4. need for mechanical ventilation
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R E S U L T S
Description of studies
In our original search, we screened 1591 titles and abstracts. We
excluded 1583 records and assessed eight in full text. Of these, two
trials did not meet our inclusion criteria and we excluded them.
One trial investigated only patients withmild hypoxaemia and had
a short follow-up of only three days (Jeantils 1993), and another
trial, Montaner 1993, was a subgroup analysis of a larger included
trial (Montaner 1990). The remaining six trials investigated adults
with HIV and moderate-severe PCP; one was only published in
abstract form (Clement 1989), two were stopped prematurely due
to apparent benefits in the treatment groups with adjunctive glu-
cocorticoid therapy (Gagnon 1990; Montaner 1990), and one
was stopped early due to published evidence from other studies
in favour of adjunctive corticosteroids (Nielsen 1992). Only three
studies were completed and published in full versions (Bozzette
1990; Nielsen 1992; Walmsley 1995).
The update search in 2010 yielded 335 records. We excluded 334
on the basis of the title and abstract. We assessed one study in full
text and subsequently included it (Terblanche 2008). This study
investigated adjunctive corticosteroid treatment in HIV-exposed
infants less than 18 months old.
For the update search in 2014, we screened 103 records as titles and
abstracts, which did not yield any further eligible studies. Overall,
we screened 2029 titles and abstracts, excluded 2020, screened
nine in full text and included seven of these in our systematic
review. Details of the included and excluded trials are provided
in the Characteristics of included studies and Characteristics of
excluded studies tables, respectively.
Risk of bias in included studies
The quality assessment for each study is shown in the ’Risk of bias’
tables in Characteristics of included studies.
Overall, the risk of bias of the six studies included in the meta-
analysis varied. Details of random sequence generation were re-
ported in three of seven studies. Patient follow-up was almost
complete for all included studies due to short follow-up periods
(the total number of patients lost to follow-up was four). In the
six studies conducted in adults, concealed allocation of partic-
ipants was reported in three studies (Bozzette 1990; Montaner
1990;Walmsley 1995). Four trials reported double-blinding with-
out specifying who was blinded (Clement 1989; Gagnon 1990;
Montaner 1990; Walmsley 1995). Three trials were single-cen-
tre (Clement 1989; Gagnon 1990: Montaner 1990), and three
weremulti-centre (Bozzette 1990;Nielsen 1992;Walmsley 1995).
Four trials reported the performance of a sample size calculation
(Bozzette 1990; Gagnon 1990; Montaner 1990; Walmsley 1995).
Two trials were stopped prematurely due to apparent treatment
benefits of adjunctive corticosteroids (Gagnon 1990; Montaner
1990), and one was stopped due to external evidence of the bene-
fits of corticosteroids (Nielsen 1992). The stopping early of clin-
ical trials for benefit may lead to an overestimation of treatment
effects due to catching the apparent benefit of treatment at a “ran-
dom high” (Montori 2005). The overall risk of bias of the study
conducted in infants was low (Terblanche 2008). Figure 1 gives
an overview of the ’Risk of bias’ assessment.
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Figure 1. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Adjunctive
corticosteroids versus no such treatment for Pneumocystis jiroveci
pneumonia in patients with HIV infection
We included seven trials in this systematic review. The six trials
included in the meta-analysis comprised a total of 242 individu-
als in the intervention groups and 247 individuals in the control
groups, with a follow-up ranging between three and 14 months.
Figure 2 (funnel plot) indicates no evidence of publication bias.
The trial in infants comprised 47 individuals in the intervention
group and 53 in the control group, who were followed up until
hospital discharge. Summary of findings for the main comparison
gives an overview of the intervention effects, with a GRADE anal-
ysis of evidence quality for each outcome.
Figure 2. Funnel plot to evaluate the presence of publication bias in trials investigating adjunctive
corticosteroids for Pneumocystis jiroveci pneumonia in HIV-infected patients. The funnel graph plots the log
of the treatment odds ratio against the standard error (SE) of the log odds ratio (an indicator of sample size).
Open circles represent trials included in the meta-analysis. The line in the centre indicates the summary log
odds ratio. In the absence of publication bias, the log odds ratio estimates from smaller trials are expected to
be scattered above and below the summary estimate, producing a symmetric triangular or funnel shape.
When smaller trials with larger log odds ratios are missing, the funnel plot appears asymmetric and may
indicate the presence of publication bias. In our systematic review the funnel plot looks symmetric. The Egger
test for publication bias was not statistically significant (P value = 0.91).
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Adjunctive corticosteroids versus placebo or usual
care
Overall mortality
Risk ratios for overall mortality were significantly reduced for ad-
junctive corticosteroids in adult patients with HIV at one month
(RR 0.56; 95% CI 0.32 to 0.98) (Analysis 1.1; Figure 3) and at
three to fourmonths of follow-up (RR 0.59; 95%CI 0.41 to 0.85)
(Analysis 1.2; Figure 4).We found some evidence of heterogeneity
among trials at one month (test of heterogeneity P value = 0.12; I2
= 43%), whereas at three to four months treatment effects looked
more homogenous (P value = 0.78; I2 = 0%). We judged the qual-
ity of the evidence for these outcomes to be high as the influence
of blinding is not of significant importance for the outcome mor-
tality.
Figure 3. Forest plot of comparison: 1 Adjunctive corticosteroids versus no such treatment, outcome: 1.1
Death at 1 month; adults.
Figure 4. Forest plot of comparison: 1 Adjunctive corticosteroids versus no such treatment, outcome: 1.2
Death at 3 to 4 months; adults.
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We explored inconsistencies among studies in sensitivity analyses.
Heterogeneity was considerably reduced when the analysis was
limited to trials reporting early adjunctive corticosteroids (within
three days) that were published in full, i.e. excluding Clement
1989 (summary risk ratio for mortality at one month 0.44; 95%
CI 0.28 to 0.69, heterogeneity P value = 0.49; I2 = 0%) (Analysis
1.6). We carried out further sensitivity analyses for the mortality
endpoint at onemonth. In trials that reported concealed allocation
(Bozzette 1990; Montaner 1990; Walmsley 1995), the summary
risk ratio was 0.54 (95% CI 0.32 to 0.92, heterogeneity P value
= 0.49; I2 = 0%) (Analysis 1.7). In trials reporting blinding of
patients and caregivers (Clement 1989; Gagnon 1990; Montaner
1990; Walmsley 1995), the summary risk ratio was 0.71 (95% CI
0.33 to 1.55, heterogeneity P value = 0.14; I2 = 44%) (Analysis
1.8). In trials not prematurely halted (Bozzette 1990; Clement
1989; Walmsley 1995), the summary risk ratio was 0.71 (95% CI
0.39 to 1.31, heterogeneity P value = 0.16; I2 = 45%) (Analysis
1.9). The assumption that patients lost to follow-up at one month
died gives a summary risk ratio of 0.56 (95% CI 0.32 to 0.97,
heterogeneity P value = 0.11; I2 = 44%) (Analysis 1.5).
The risk ratio for in-hospital mortality in infants receiving adjunc-
tive corticosteroids was 0.81 (95% CI 0.51 to 1.29) (Terblanche
2008) (Analysis 1.3; Figure 5). We downgraded the quality of the
evidence for this outcome from high to moderate as there was
only one trial available, with a wide confidence interval including
clinically relevant benefit and harm.
Figure 5. Forest plot of comparison: 1 Adjunctive corticosteroids versus no such treatment, outcome: 1.3
Death in hospital; children.
Need for mechanical ventilation
Reliable data on the need for mechanical ventilation were only
available for the three largest trials (Bozzette 1990; Nielsen 1992;
Walmsley 1995). Again, the risk ratio for this endpoint was largely
reduced in the group with early adjunctive corticosteroids (0.38;
95%CI 0.20 to 0.73; P value = 0.40; I2 = 0%) (Analysis 1.4; Figure
6). We downgraded the quality of the evidence for this outcome
from high to moderate because lack of blinding could influence
the decision of a caregiver to initiate mechanical ventilation.
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Figure 6. Forest plot of comparison: 1 Adjunctive corticosteroids versus no such treatment, outcome: 1.4
Need for mechanical ventilation at 1 month; adults.
D I S C U S S I O N
The meta-analysis of six randomised controlled trials in HIV-in-
fected adults withPneumocystis jiroveci pneumonia (PCP) and sub-
stantial hypoxaemia found a significant reduction in the relative
risk of death with adjunctive corticosteroids of 44% at one month
and 41% at three to four months. The average weighted mean
mortality in the control groups of these trials at one month was
25%. This initial mortality rate of 25% can be assumed in settings
where highly active antiretroviral therapy (HAART) is not avail-
able, which is still the case for most developing countries (Fisk
2003). In this situation we estimated that nine (95% confidence
interval (CI) 6 to 200) HIV-infected adults with PCP have to be
treated early with adjunctive corticosteroids to prevent one death
during the first month after PCP diagnosis. In Western countries,
where HAART is widely available, we estimated the respective
number needed to treat to be 23 patients (95% CI 15 to 500),
assuming an initial mortality rate of 10% (Sepkowitz 2002). With
regard to the need for mechanical ventilation, the risk reduction
with adjunctive corticosteroids was even greater in the investigated
patient population, but the number of trials was small (n = 3).
Only one trial reported overall mortality during the hospitalisation
of infants under 18 months of age diagnosed with PCP. There was
insufficient evidence to be certain that adjunctive corticosteroids
had an effect on mortality (confidence intervals were wide, includ-
ing both clinically relevant benefit and harm). Due to limited re-
sources, the authors of that trial fixed the number of participating
infants at 100 (Terblanche 2008).
This review has several strengths and limitations. We conducted
an extensive literature search and updates to retrieve all eligible
trials. However, formal testing for publication bias was not pow-
erful because of the small number of included trials. Even with a
symmetric funnel plot (Figure 2), such bias cannot be ruled out.
Moreover, with a small number of included trials the uncertainty
interval for the inconsistency among trials may not be very in-
formative (Higgins 2003). We focused mainly on mortality data,
which may be less prone to ascertainment bias, and we analysed
the data according to the intention-to-treat principle to get more
conservative estimates. Finally, the trials included in this meta-
analysis used different corticosteroid regimens. So far, neither the
dosing nor the length and tapering schedule of corticosteroids has
been adequately addressed in randomised trials. In former and cur-
rent recommendations for adults (Benson 2004; CDC 2013), the
corticosteroid schedule of the largest trial was adapted (Bozzette
1990). The former (Frieden 2009) and current guidelines (NIH
2013) for children have taken the trials in adults into account as
well as three comparative observational studies in children (Bye
1994; McLaughlin 1995; Sleasman 1993).
There has been some concern among physicians treating patients
with AIDS that further immunosuppression due to corticosteroid
therapy could accelerate the onset of other HIV-related oppor-
tunistic complications (Lambertus 1990; Nelson 1993). However,
with the exception of an increase in muco-cutaneous herpes sim-
plex infection episodes (Bozzette 1990), adjunctive corticosteroids
were not associated with an increase in opportunistic complica-
tions in any of the included trials. A large cohort study that used
a standard 21-day tapering course of adjunctive corticosteroids
found no difference in the risk of AIDS-related complications
apart from an increase in oesophageal candidiasis (Gallant 1998).
It is possible that adjunctive corticosteroids are also beneficial for
HIV-infected patients with mild hypoxaemia due to PCP (Jeantils
1993). However, in this situation the short-term mortality is low
and possible unfavourable effects of corticosteroids might out-
weigh the benefits. Evidence from randomised controlled trials
for non-HIV-infected patients with severe PCP is still lacking.
Retrospective observational studies have shown conflicting results:
while Pareja 1998 found that corticosteroids might be beneficial,
Delclaux 1999 and Moon 2011 did not find an improvement of
outcomes in non-HIV-infected patients with severe PCP.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review has confirmed and quantified the benefit
of adjunctive corticosteroid therapy in HIV-infected adults with
moderate-severe Pneumocystis jiroveci pneumonia (PCP). We esti-
mated a relative risk reduction for overall mortality of 44% at one
month and 41% at three to four months. We calculated that nine
patients must be treated with adjunctive corticosteroids in order
to prevent one death in a setting where highly active antiretroviral
therapy (HAART) is not available, and that 23 patients must be
treated with adjunctive corticosteroids to prevent one death in a
settingwhereHAART is available. The results corroborate the con-
clusions of the 1990 consensus statement (Consensus 1990), and
support current recommendations for the management of PCP in
HIV-infected adults (CDC 2013). In adults, it is recommended to
start the corticosteroid treatment as early as possible but within 72
hours after starting the PCP-specific therapy. The recommended
dose for prednisone is 40 mg orally twice daily for days one to
five, 40 mg once daily for days six to 10, and 20 mg once daily for
days 11 to 21 (Benson 2004; EACS 2013). If parenteral adminis-
tration is necessary, it is recommended to use methylprednisolone
at 75% of the respective prednisone dose (CDC 2013). In chil-
dren with severe PCP, it is recommended to start the corticosteroid
treatment as early as possible but within 72 hours after diagnosis.
The recommended dose of prednisone is 1 mg/kg of body weight
twice daily for days one to five, 0.5 mg/kg once daily for days six
to 10, and 0.5 mg/kg once daily for days 11 to 21 (NIH 2013).
The alternative regimen with methylprednisolone (intravenous)
is 1 mg/kg/dose every six hours for days one to seven, 1 mg/kg/
dose once daily for days eight to nine, 0.5 mg/kg/dose twice daily
for days 10 to 11, and 1 mg/kg/dose once daily for days 12 to 16
(NIH 2013).
Implications for research
This systematic review has confirmed and quantified the benefit
of adjunctive corticosteroid therapy in HIV-infected adults with
moderate-severe PCP. The results underline the conclusions of the
1990 consensus statement (Consensus 1990), and support current
recommendations for the management of PCP in HIV-infected
patients (CDC 2013; NIH 2013). More research regarding ad-
junctive corticosteroids in HIV-infected infants is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bozzette 1990
Methods Prospective, randomised, parallel-group, unblinded trial
Max. follow-up: 84 days
Sample size calculation performed
Trial completed as planned
Participants 251 patients with AIDS and confirmed or presumed PCP and hypoxaemia ratio (partial
pressure of arterial oxygen divided by fraction of inspired oxygen) > 75
Diagnosis of PCP: 75% bronchoalveolar lavage, 15% sputum, 10% clinically presumed
Baseline treatment for PCP: 80% trimethoprim-sulfamethoxazole (15 to 20 mg
trimethoprim per kg body weight per day oral or parenteral), 18% pentamidine (3 to 4
mg per kg per day parenteral), 2% dapsone (100 mg per day oral)
Recruitment: June 1987 to June 1989
Study centres: 6
Country: USA
Setting: tertiary care
% male: 97
Mean age: 36 years
Baseline characteristics similar for each group: yes
Interventions Adjunctive prednisone (oral), 40 mg twice daily for 5 days, followed by 40 mg daily
for 5 days, followed by 20 mg daily for the duration of anti-pneumocystis therapy.
Patients unable to take oral medication received parenteral methylprednisolone (75% of
respective prednisone doses)
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroid: 36 hours
Control: no additional treatment. Patients with respiratory failure could be prescribed
corticosteroids at the discretion of the primary physician (41% of patients (7 of 17)
with respiratory failure in the corticosteroid group; 60% of patients (15 of 25) with
respiratory failure in the control group)
Outcomes 1. Occurrence of respiratory failure (hypoxaemia ratio (partial pressure of arterial oxygen
divided by fraction of inspired oxygen) < 75), intubation or death
2. Death
3. Dose-limiting toxicity of the initial standard therapy
Notes Funding: California University-Wide AIDS Research Program
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was prepared centrally
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Bozzette 1990 (Continued)
Allocation concealment (selection bias) Unclear risk Quote: “The randomization was prepared
centrally, with blocks of four patients per
stratum and a 1:1 proportion; it was car-
ried out bymeans of sealed envelopes at the
study sites.”
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up in the corticosteroid
group was 1 patient (1%) and in the con-
trol group 3 patients (2%)
Other bias Low risk Sample size calculation performed. Trial
completed as planned
Clement 1989
Methods Prospective, randomised, parallel-group trial with “double-blinding”
Max. follow-up: 56 days
Sample size calculation not reported
Participants 41 patients with confirmed PCP and an arterial partial pressure of oxygen below 50
mmHg on room air. Diagnosis of PCP: bronchoalveolar lavage or sputum
Baseline treatment for PCP: 88% trimethoprim-sulfamethoxazole, 12% pentamidine
Recruitment period not reported
Study centres: 1
Country: USA
Setting: tertiary care
% male: not reported
Age: not reported
Methylprednisolone group: PaO2 = 280 mmHg, LDH = 600; placebo group: PaO2 =
290 mmHg, LDH = 718 (difference not significant); no other baseline characteristics
reported
Interventions Adjunctive methylprednisolone (intravenous), 60mg every 6 hours for 2 days, then every
12 hours for 2 days, then once 60 mg, then 40 mg, then 20 mg, then 10 mg for 1 day
each
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroid: not explicitly stated (29/41 patients received steroids/placebo≥ 48 hours)
Control: placebo
Outcomes Survival at 56 days
Notes The study was only published in abstract form
Funding: not reported
Registration: not reported
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Clement 1989 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Patients were randomized to re-
ceive placebo (P) or intravenous methyl-
prednisolone (MP) as adjunctive ther-
apy the assignment being double-blinded.
” Who was blinded is not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “We prospectively enrolled 41 con-
secutive, consenting adults with docu-
mented PCP (by sputum induction or
broncho-alveolar lavage).” At the end of
follow-up (56 days) survival status was re-
ported for all 41 patients
Other bias Unclear risk Inadequate information available
Gagnon 1990
Methods Prospective, randomised, parallel-group, “double-blind, placebo-controlled” trial
Max. follow-up: 14 months
Sample size calculation performed (80 patients)
Trial stopped prematurely for benefit at interim analysis (enrolment of 23 patients)
Participants 23 patients with HIV infection, engaged in behaviour placing them at risk of HIV
infection, or with oral candidiasis at entry into the study and severe PCP, defined by a
respiratory rate above 30 breaths per minute at rest, an alveolar-arterial oxygen difference
above 30 mmHg while the patient breathed room air, and an arterial partial pressure of
oxygen below 75 mmHg while the patient breathed 35% oxygen through a face mask
but above 60 mmHg while the patient breathed 100% oxygen through a face mask.
Intubated patients were excluded as well as patients with a history of hypersensitivity
to both trimethoprim-sulfamethoxazole and pentamidine, a serum creatinine level > 3
times the upper limit of normal, an absolute neutrophil count below 1 x 109 cells per
litre, and treatment with corticosteroids within a period of 2 weeks before study entry
Diagnosis of PCP: histology from bronchoalveolar lavage, biopsy or sputum
Baseline treatment for PCP: 100% trimethoprim-sulfamethoxazole at 15 mg/kg/day
trimethoprim for 21 days. Modification of the treatment in the case of toxicity according
to the protocol by Sattler et al (Sattler 1988)
Recruitment: June 1989 to May 1990
Study centres: 1
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Gagnon 1990 (Continued)
Country: USA
Setting: tertiary care
% male: 83
Mean age (range): 38 (23 to 66) years
Baseline characteristics similar for each group: yes
Interventions Adjunctive methylprednisolone (intravenous), 40 mg every 6 hours for 7 days, followed
by a tapering dose for 3 days in patients with a clinical relapse
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroids: < 72 hours
Control: placebo
Outcomes 1. Survival until hospital discharge
2. Development of respiratory failure (defined as an arterial oxygen pressure > 60 mmHg
while the patient breathed≥ 60% oxygen through a face mask or rising partial pressure
of carbon dioxide, in addition to need for intubation) and the completion of antibiotic
therapy
Notes Funding: Alliance Against AIDS, Miami
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation in blocks of 10 but how
the randomisation was actually performed
is not described
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind” placebo-controlled study
but who was blinded is not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. No changes from in-
tervention group to placebo group or vice
versa
Other bias High risk Trial stopped early for benefit
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Montaner 1990
Methods Prospective, randomised, parallel-group, “double blind, placebo-controlled” trial
Max. follow-up: 90 days
Sample size calculation performed (70 patients; sequential analysis with triangular test)
Trial stopped prematurely for benefit (enrolment of 37 patients)
Participants 37 patients > 18 years with known HIV and first episode of confirmed PCP, and oxygen
saturation by pulse oximetry of 85% or more and less than 90% at rest or a 5-percentage-
point decrease in oxygen saturation with exercise while breathing room air. Exclusion
criteria: current treatment with systemic corticosteroids or prior treatment within 30
days, active pulmonary pathology other than PCP, cytomegalovirus disease, need for
mechanical ventilation prior to randomisation, contraindication to corticosteroids (for
example, uncontrolled hypertension, psychosis, active peptic ulcer or mycobacterial dis-
ease)
Diagnosis of PCP: 100% bronchoalveolar lavage
Baseline treatment for PCP: trimethoprim-sulfamethoxazole (20 mg/kg and 100 mg/kg
per day oral or intravenous qid), pentamidine (4 mg/kg per day, intravenous), dapsone-
trimethoprim (100 mg oral od and 20 mg/kg per day oral qid) for at least 14 days
Recruitment: ? to April 1989
Study centres: 1
Country: Canada
Setting: tertiary care
% male: 95
Median age: not reported
Baseline characteristics similar for each group: only CD4 cell count reported
Interventions Adjunctive prednisone (Deltasone, oral), 60 mg daily for 7 days, followed by 50 mg,
then 40 mg, 30 mg, 20 mg, 15 mg, 10 mg, 5 mg daily (each for 2 days)
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroid: 48 hours
Control: placebo
Outcomes Early deterioration defined by a 10% decrease in baseline oxygen saturation at rest
occurring not before day 3
Notes Funding: National Health Research Development Programme (NHRDP), Department
of Health and Welfare, Canada
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out by the hos-
pital pharmacy according to a computer-
generated table
Allocation concealment (selection bias) Low risk Quote: “Randomization was carried out in
blocks of ten patients by the hospital phar-
macy according to a computer-generated
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Montaner 1990 (Continued)
table of random numbers. Individual pre-
sealed envelopes were used to keep each pa-
tient’s code.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “double-blind placebo-controlled trial”.
Who was blinded was not described. Low
risk of detection bias for mortality. For all
8 placebo patients with early deterioration
the seal was broken and treatmentwith cor-
ticosteroids initiated
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Other bias High risk Trial stopped early for benefit
Nielsen 1992
Methods Prospective, randomised, parallel-group, unblinded trial
Max. follow-up: 90 days
Sample size calculation not reported
Trial stopped prematurely due to external evidence in favour of adjunctive corticosteroids
Participants 59 patients with HIV and a first episode of confirmed PCP, and an arterial partial
pressure of oxygen below 67.5 mmHg and/or an arterial partial pressure of CO2 below
30 mmHg on room air. Exclusion criteria: unconfirmed PCP within 72 hours after anti-
PCP treatment, treatment with cotrimoxazole or corticosteroids in the preceding 14
days, concomitant (myco-)bacterial pulmonary infection diagnosed by microscopy of
the bronchoalveolar lavage, uncontrolled diabetes mellitus, pregnancy or age < 18 years
Diagnosis of PCP: histology of bronchoalveolar lavage or biopsy
Baseline treatment for PCP: 100% trimethoprim-sulfamethoxazole (15 mg trimetho-
prim/75 mg sulfamethoxazole per kg per day) in 4 divided doses for at least 14 days.
The medication was given intravenous on day 1 to 10 and then oral administration was
allowed. Patients with intolerance 2% (1 patient) or lack of clinical response to cotri-
moxazole 14% (8 patients) changed to pentamidine (4 mg per kg intravenous per day)
Recruitment: October 1988 to May 1990
Study centres: 3
Country: Denmark, Netherlands
Setting: tertiary care
% male: 95
Median age (range): 37 (26 to 68)
Baseline characteristics similar for each group: yes
Interventions Adjunctive methylprednisolone (intravenous), 2 mg/kg body weight every 6 hours for
10 days
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroid: < 24 hours
Control: no additional treatment
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Nielsen 1992 (Continued)
Outcomes 1. Survival to discharge from hospital
2. Survival at day 90
3. Need for mechanical ventilation during the initial episode
Notes Funding: not reported
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block randomisation but no further details
given
Allocation concealment (selection bias) Unclear risk Not reported (see above)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label trial; low risk of detection bias
for the outcome mortality
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up. No changes from
treatment to control group or vice-versa
Other bias High risk Sample size calculation not reported. Trial
stopped prematurely due to external ev-
idence in favour of adjunctive corticos-
teroids
Terblanche 2008
Methods Prospective, randomised, placebo-controlled trial. Trial is “double-blind” but who was
blinded was not reported
Follow-up until hospital discharge
Sample size calculation: not reported. Number restricted to 100 participants due to time
and financial constraints
Trial completed as planned
Participants 100 infants who had been exposed to HIV with severe pneumonia, which was confirmed
or clinically suspected to be caused by Pneumocystis jiroveci
Oxygenation: no entry criteria reported.Mean oxygen saturation in a) prednisone group:
69% (SD 15.8), b) placebo 72% (SD 13.8)
Clinical diagnosis of PCP: patients with “atypical” pneumonia with the following fea-
tures: a) hypoxia out of proportion to the clinical findings on auscultation; b) C-reactive
protein (CRP) count < 10 mg/l or low; c) lactate dehydrogenase (LDH) level > 500 IU/
l; d) bilateral perihilar interstitial infiltrates on chest radiograph (CXR) compatible with
a diagnosis of PCP; and e) positive HIV enzyme-linked immunosorbent assay (ELISA)
Patients who were still hospitalised on day 7 had induced sputum and nasopharyngeal
aspirates collected
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Terblanche 2008 (Continued)
For the results of the virological testing see: Table 1
Baseline treatment for PCP: “Standard antibiotic regimen including co-trimoxazole”
Recruitment: February 2005 to 31 March 2006
Study centres: 3
Country: South Africa
Setting: university hospitals
% male: 52
Mean age in months (SD): prednisone group: 3.4 (2), placebo group: 3.2 (1.4)
Baseline characteristics similar for each group: yes
Interventions Adjunctive prednisone 2 mg/kg/day for 7 days
Control: placebo
36% (17/47 patients) in the intervention group and 42% (22/53 patients) in the placebo
group received additional prednisone at 48 hours due to clinical deterioration or an
independent indication for steroid therapy
Outcomes 1. In-hospital survival (intention-to-treat and per-protocol analysis both unadjusted and
adjusted for age and hospital)
2. Independence of oxygen (intention-to-treat and per-protocol analysis both unadjusted
and adjusted for age and hospital)
3. Subgroup analysis for clinically less ill patients
Notes Funding: not reported
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of random number generator
Allocation concealment (selection bias) Low risk Quote: “A random number generator was
used to determine the allocation to steroid
or placebo treatment, which were provided
in a double-blind fashion by the hospital
pharmacists according to study number.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind, placebo-controlled trial”,
but who was blinded is not explained
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Survival documented for all included pa-
tients. The fact that additional steroids
could be given could lead to an underesti-
mation of the treatment effect in the analy-
sis following the intention-to-treat princi-
ple
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Terblanche 2008 (Continued)
Other bias Unclear risk Sample size calculation: not reported.
Number restricted to 100 participants due
to time and financial constraints. Trial
completed as planned
Walmsley 1995
Methods Prospective, randomised, parallel-group, “double-blind”, placebo-controlled trial
Max. follow-up for clinical outcomes: 6 months
Sample size calculation performed (70 patients)
Trial completed as planned
Participants 78 patients with known or suspected HIV infection and confirmed first or recurrent
episode of PCP, and an arterial partial pressure of oxygen below 70 mmHg while the
patient breathed room air or an alveolar-arterial oxygen gradient above 40 mmHg if
arterial blood gases could not be assessed on room air. Exclusion criteria: < 18 years,
contraindication to corticosteroids (active gastrointestinal bleeding in the previous 3
months, ocular herpes simplex infection, poorly controlled diabetes mellitus), more than
1 significant pathogen found on direct examination of the initial pulmonary specimen
(i.e. acid-fast bacilli), extensive Kaposi’s sarcoma of the respiratory tract seen at bron-
choscopy, or treatment with systemic corticosteroids for any reason in the 3months prior
to randomisation
Diagnosis of PCP: bronchoalveolar lavage, biopsy, sputum
Baseline treatment for PCP: 82% trimethoprim-sulfamethoxazole (15 to 20 mg
trimethoprim per kg per day intravenous or oral), 17% pentamidine (3 to 4 mg per kg
per day oral), 1% dapsone (100 mg per day) plus trimethoprim (15 to 20 mg per kg per
day) for 21 days. Patients intolerant or failing to respond to their initial PCP therapy
could be switched to another form of either standard or salvage treatment (eflornithine,
4% (3 patients))
Recruitment: August 1986 to January 1991
Study centres: 3
Country: Canada
Setting: tertiary care
% male: 99
Mean age: 37
Baseline characteristics similar for each group: yes
Interventions Adjunctive methylprednisolone (intravenous), 40 mg every 12 hours for 10 days
Maximal interval between initiation of baseline treatment for PCP and initiation of
corticosteroid: < 24 hours
Control: placebo
Patients could receive steroids outside the study protocol based on the clinical judgement
of the treating physician; the seal was not broken in those cases. 16 patients received
corticosteroids outside the study protocol: 6 patients in the intervention group and 10
patients in the placebo group
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Walmsley 1995 (Continued)
Outcomes 1. Composite of death before hospital discharge, requirement for mechanical ventilation
for 6 or more days, failure to achieve an arterial partial pressure of oxygen > 70 mmHg
on room air by day 10 of therapy
2. Adverse drug reactions resulting in discontinuation of the antimicrobial medication
3. Time to defervescence
4. Time to improvement of chest radiographs
5. Superinfections during acute therapy
6. Opportunistic infections or malignancies in the 6 months after treatment
7. Potential adverse reactions to corticosteroids, including hypertension, hyperglycaemia,
gastrointestinal bleeding and neuropsychiatric disturbances
Notes There was no statistically significant difference in the primary endpoint between ran-
domised groups
The study was published 4 years after its completion
Funding: grants from the National Health Research and Development Program
(NHRDP),Grant 6606-3373-AIDS, and the SunnybrookHealth SciencesCenter Foun-
dation for Research
Registration: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details described
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed by
the random numbers method in a 1:1 ra-
tion by the TGH pharmacy department,
and blocks of randomization codes were
forwarded to participating centers.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind placebo-controlled trial”,
but who was blinded is not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up but 10 patients in the
placebo group received the intervention:
might cause bias and lead to an underesti-
mate of the true treatment effect
Other bias Low risk Sample size calculation performed (70 pa-
tients). Trial completed as planned
LDH: lactate dehydrogenase
PCP: Pneumocystis jiroveci pneumonia
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Jeantils 1993 Small pilot study on 10 patients with no or mild hypoxaemia (arterial partial pressure of oxygen above 70 mmHg)
and a follow-up of only 3 days; no mortality
Montaner 1993 Study on a subgroup of patients from the already included study Montaner 1990
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D A T A A N D A N A L Y S E S
Comparison 1. Adjunctive corticosteroids versus no such treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death at 1 month; adults 6 489 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.32, 0.98]
2 Death at 3 to 4 months; adults 5 448 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.41, 0.85]
3 Death in hospital; children 1 100 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.51, 1.29]
4 Need for mechanical ventilation
at 1 month; adults
3 388 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.20, 0.73]
5 Sensitivity analysis: Death
at 1 month; adults; loss to
follow-up = dead
6 489 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.32, 0.97]
6 Sensitivity analysis: Death at
1 month; adults; without
Clement 1989
5 448 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.28, 0.69]
7 Sensitivity analysis: Death at
1 month; adults; concealed
allocation only
3 366 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.32, 0.92]
8 Sensitivity analysis: Death at
1 month; adults; blinding of
patients and caregivers
4 179 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.33, 1.55]
9 Sensitivity analysis: Death at
1 month; adults; trials not
prematurely halted
3 370 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.39, 1.31]
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Analysis 1.1. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 1 Death at 1
month; adults.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 1 Death at 1 month; adults
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 13/123 28/128 28.1 % 0.48 [ 0.26, 0.89 ]
Clement 1989 9/19 9/22 25.7 % 1.16 [ 0.58, 2.31 ]
Gagnon 1990 3/12 9/11 17.6 % 0.31 [ 0.11, 0.85 ]
Montaner 1990 1/18 0/19 3.0 % 3.16 [ 0.14, 72.84 ]
Nielsen 1992 2/30 9/29 11.1 % 0.21 [ 0.05, 0.91 ]
Walmsley 1995 4/40 6/38 14.6 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 242 247 100.0 % 0.56 [ 0.32, 0.98 ]
Total events: 32 (Treatment), 61 (Control)
Heterogeneity: Tau2 = 0.19; Chi2 = 8.83, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 2 Death at 3 to
4 months; adults.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 2 Death at 3 to 4 months; adults
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 20/123 33/128 52.3 % 0.63 [ 0.38, 1.04 ]
Gagnon 1990 5/12 9/11 24.6 % 0.51 [ 0.25, 1.05 ]
Montaner 1990 2/18 1/19 2.4 % 2.11 [ 0.21, 21.32 ]
Nielsen 1992 4/30 9/29 11.5 % 0.43 [ 0.15, 1.24 ]
Walmsley 1995 4/40 6/38 9.2 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 223 225 100.0 % 0.59 [ 0.41, 0.85 ]
Total events: 35 (Treatment), 58 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.77, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 3 Death in
hospital; children.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 3 Death in hospital; children
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Terblanche 2008 18/47 25/53 100.0 % 0.81 [ 0.51, 1.29 ]
Total (95% CI) 47 53 100.0 % 0.81 [ 0.51, 1.29 ]
Total events: 18 (Treatment), 25 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.4. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 4 Need for
mechanical ventilation at 1 month; adults.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 4 Need for mechanical ventilation at 1 month; adults
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 5/123 15/128 42.6 % 0.35 [ 0.13, 0.93 ]
Nielsen 1992 3/30 12/29 30.6 % 0.24 [ 0.08, 0.77 ]
Walmsley 1995 4/40 5/38 26.8 % 0.76 [ 0.22, 2.62 ]
Total (95% CI) 193 195 100.0 % 0.38 [ 0.20, 0.73 ]
Total events: 12 (Treatment), 32 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 5 Sensitivity
analysis: Death at 1 month; adults; loss to follow-up = dead.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 5 Sensitivity analysis: Death at 1 month; adults; loss to follow-up = dead
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 14/123 31/128 28.7 % 0.47 [ 0.26, 0.84 ]
Clement 1989 9/19 9/22 25.4 % 1.16 [ 0.58, 2.31 ]
Gagnon 1990 3/12 9/11 17.5 % 0.31 [ 0.11, 0.85 ]
Montaner 1990 1/18 0/19 3.0 % 3.16 [ 0.14, 72.84 ]
Nielsen 1992 2/30 9/29 11.0 % 0.21 [ 0.05, 0.91 ]
Walmsley 1995 4/40 6/38 14.5 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 242 247 100.0 % 0.56 [ 0.32, 0.97 ]
Total events: 33 (Treatment), 64 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 8.99, df = 5 (P = 0.11); I2 =44%
Test for overall effect: Z = 2.06 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 6 Sensitivity
analysis: Death at 1 month; adults; without Clement 1989.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 6 Sensitivity analysis: Death at 1 month; adults; without Clement 1989
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 13/123 28/128 54.4 % 0.48 [ 0.26, 0.89 ]
Gagnon 1990 3/12 9/11 19.5 % 0.31 [ 0.11, 0.85 ]
Montaner 1990 1/18 0/19 2.1 % 3.16 [ 0.14, 72.84 ]
Nielsen 1992 2/30 9/29 9.7 % 0.21 [ 0.05, 0.91 ]
Walmsley 1995 4/40 6/38 14.4 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 223 225 100.0 % 0.44 [ 0.28, 0.69 ]
Total events: 23 (Treatment), 52 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00036)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 7 Sensitivity
analysis: Death at 1 month; adults; concealed allocation only.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 7 Sensitivity analysis: Death at 1 month; adults; concealed allocation only
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 13/123 28/128 76.8 % 0.48 [ 0.26, 0.89 ]
Montaner 1990 1/18 0/19 2.9 % 3.16 [ 0.14, 72.84 ]
Walmsley 1995 4/40 6/38 20.3 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 181 185 100.0 % 0.54 [ 0.32, 0.92 ]
Total events: 18 (Treatment), 34 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.42, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 8 Sensitivity
analysis: Death at 1 month; adults; blinding of patients and caregivers.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 8 Sensitivity analysis: Death at 1 month; adults; blinding of patients and caregivers
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clement 1989 9/19 9/22 40.3 % 1.16 [ 0.58, 2.31 ]
Gagnon 1990 3/12 9/11 29.3 % 0.31 [ 0.11, 0.85 ]
Montaner 1990 1/18 0/19 5.5 % 3.16 [ 0.14, 72.84 ]
Walmsley 1995 4/40 6/38 24.9 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 89 90 100.0 % 0.71 [ 0.33, 1.55 ]
Total events: 17 (Treatment), 24 (Control)
Heterogeneity: Tau2 = 0.26; Chi2 = 5.40, df = 3 (P = 0.14); I2 =44%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Adjunctive corticosteroids versus no such treatment, Outcome 9 Sensitivity
analysis: Death at 1 month; adults; trials not prematurely halted.
Review: Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection
Comparison: 1 Adjunctive corticosteroids versus no such treatment
Outcome: 9 Sensitivity analysis: Death at 1 month; adults; trials not prematurely halted
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bozzette 1990 13/123 28/128 42.5 % 0.48 [ 0.26, 0.89 ]
Clement 1989 9/19 9/22 38.0 % 1.16 [ 0.58, 2.31 ]
Walmsley 1995 4/40 6/38 19.5 % 0.63 [ 0.19, 2.07 ]
Total (95% CI) 182 188 100.0 % 0.71 [ 0.39, 1.31 ]
Total events: 26 (Treatment), 43 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 3.65, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Results of virological testing in Terblanche 2008
Treatment group PCP PCR in sputum PCP IF Nasopharyngeal aspirate for respiratory viruses
Prednisone group 5/9 3/39 RSV: 1/41
CMV: 1/41
Placebo group 3/6 5/46 RSV: 7/47
Adenovirus: 1/47
Influenza A: 2/47
Parainfluenza 3: 1/47
PCP: Pneumocystis jiroveci pneumonia
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A P P E N D I C E S
Appendix 1. PubMed search strategy
Search Most recent queries
#5 Search #1 AND #2 AND #3 AND #4 Limits: Publication Date from 2004/12/01 to 2010/08/30
#4 Search steroids[mh:noexp] OR adrenal cortex hormones[mh:noexp] OR steroid*[tiab] OR adrenal cortex hormones[tiab]
OR glucocorticoids[mh] OR glucocorticoid*[tiab] OR corticosteroid*[tiab] OR Pneumonia, Pneumocystis/drug ther-
apy[mh]
#3 Search PCP OR pneumonia, pneumocystis[mh] OR pneumocystis[tiab] OR pneumocystis jirovecii[mh] OR jiroveci[tiab]
OR jirovecii[tiab] OR pneumocystis infections[mh] OR pneumocystis carinii[mh] OR carinii[tiab] OR carinus[tiab] OR
carini[tiab]
#2 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug
therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
#1 Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw]
OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-
deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR
acquired immunodeficiency syndrome[tw]OR acquired immunedeficiency syndrome[tw]OR acquired immuno-deficiency
syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw]))
OR “sexually transmitted diseases, viral”[MESH:NoExp]
WH A T ’ S N E W
Last assessed as up-to-date: 11 April 2014.
Date Event Description
7 January 2015 New citation required but conclusions have not changed No new studies identified. This review will not be up-
dated again
7 January 2015 New search has been performed Complete update of the review.
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H I S T O R Y
Review first published: Issue 3, 2006
Date Event Description
11 April 2014 New search has been performed Literature searches updated:
- 11 Ap ril 2014: EMBASE, PubMed, CENTRAL,
Clinical Trials.gov, WHO ICTRP, AEGIS
8 September 2010 New search has been performed Literature searches updated:
- 8 September 2010: EMBASE
- 9 September 2010: CENTRAL, WHO ICTRP, Clin-
icalTrials.gov
- 17 September 2010: PubMed, AEGIS
29 October 2008 Amended Converted to new review format.
24 May 2006 New citation required and conclusions have changed Substantive amendment.
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